Home > Insider Trading > Filing (0001140361-15-007863)

Filing Details

Accession Number:: 0001140361-15-007863
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-02-18 18:33:34
Reporting Period:: 2015-02-14

Filing Date:: 2015-02-18
Accepted Time:: 2015-02-18 18:33:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219445	P Brian Mckeon	One Idexx Drive Westbrook ME 04092	Executive Vp, Cfo & Treasurer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-02-14	363	$0.00	14,562	No	4	M	Direct
Common Stock	Disposition	2015-02-14	117	$159.08	14,445	No	4	F	Direct
Common Stock	Acquisiton	2015-02-17	5,000	$29.27	19,445	No	4	M	Direct
Common Stock	Disposition	2015-02-17	2,000	$156.44	17,445	No	4	S	Direct
Common Stock	Disposition	2015-02-17	3,000	$157.36	14,445	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Acquisiton	2015-02-14	18,108	$0.00	18,108	$159.08
Common Stock	Incentive Stock Option (right to buy)	Acquisiton	2015-02-14	628	$0.00	628	$159.08
Common Stock	Restricted Stock Unit	Acquisiton	2015-02-14	1,572	$0.00	1,572	$0.00
Common Stock	Restricted Stock Unit	Disposition	2015-02-14	363	$0.00	363	$0.00
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2015-02-17	5,000	$0.00	5,000	$29.27

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,108	2025-02-13	No	4	A	Direct
628	2025-02-13	No	4	A	Direct
9,027		No	4	A	Direct
8,664		No	4	M	Direct
0	2015-05-17	No	4	M	Direct

Footnotes

The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/20/2014.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.91 to $156.84, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.91 to $157.90, inclusive.
Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that becomes exercisable as to 3,748 shares on 02/14/2016, 3,747 shares on 02/14/2017, 02/14/2018 and 02/14/2019, and the remaining 3,119 shares on 02/14/2020.
Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests on the fifth anniversary date (02/14/2020) of the grant.
Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2016) of the date of grant.
Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vested in five equal annual installments, beginning on the first anniversary date (02/14/2015) of the date of grant.
Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested fully on 05/10/2006.